Skip to content
metaboliq

Mounjaro vs Ozempic: how they differ, what each is approved for in India

Mounjaro is tirzepatide and acts on two gut hormone receptors; Ozempic is semaglutide and acts on one. In the head-to-head trial tirzepatide reduced body weight more. Their approved uses differ in India, both are prescription-only, and a doctor decides which, if either, fits you.

Mounjaro
Tirzepatide (GIP and GLP-1), Eli Lilly; approved in India for type 2 diabetes and chronic weight management in adults.
Ozempic
Semaglutide (GLP-1), Novo Nordisk; approved for type 2 diabetes in adults.
Both
Once a week, under the skin, from a pen.
Who decides
A doctor, after your history and blood tests.

One receptor or two

Ozempic's semaglutide acts on the GLP-1 receptor. Mounjaro's tirzepatide acts on GLP-1 and on GIP, a second gut hormone receptor. Both slow stomach emptying, increase fullness and help the body handle blood sugar.

Sources: [1], [2]

The head-to-head trial

SURMOUNT-5 compared the highest tolerated strength of each, tirzepatide against semaglutide 2.4 mg, for 72 weeks. Average body-weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide.

In the first Indian cohort study, results at about six months were smaller than trial averages for both, and larger with tirzepatide.

Sources: [3], [4]

Approved uses in India

Mounjaro is approved in India for type 2 diabetes in adults and for chronic weight management in adults. Ozempic is approved for type 2 diabetes in adults; the semaglutide approved in India for chronic weight management is Wegovy, 2.4 mg.

The regulator has asked states to keep these products to their approved uses and labelling.

Sources: [5], [1], [6], [7]

Side effects compared

Both cause the same kind of stomach side effects, mainly nausea, diarrhoea, vomiting and constipation, most often in the first weeks and after each step up. The serious risks listed on both labels are the same family: pancreatitis, gallbladder problems and dehydration.

Sources: [1], [2]

Who decides, and how it is started

It is prescription-only in India, and a doctor decides whether it fits you after reading your history, your blood tests and anything else you take.

It is started at a low strength and stepped up every four weeks or so, because stepping up slowly is what keeps the stomach side effects manageable.

Sold outside an authorised pharmacy, a pen can be fake, wrongly stored or the wrong strength; the regulator has asked states to keep these products to authorised channels and their approved uses.

Sources: [7]

Why muscle matters

Body weight falls as fat and as lean tissue together. In the STEP 1 body-composition substudy, roughly 40% of the total lost was lean mass.

Muscle is what keeps blood sugar handled well, keeps you strong as you age and keeps your daily energy use up. So the plan around any treatment protects it: protein at every meal, strength training two or three times a week, and body composition measured rather than the scale alone.

Sources: [8]

What happens when it is stopped

These work while they are taken. One year after semaglutide was stopped in the STEP 1 extension, people had regained about two-thirds of what they had lost; in SURMOUNT-4, people switched from tirzepatide to placebo regained about 14% of body weight.

That is why the habits built alongside treatment, and a plan for maintenance, matter as much as the treatment itself.

Sources: [9], [10]

Side effects

Common, and usually easing with time

  • Nausea, most often in the first weeks and after each step up.
  • Diarrhoea or constipation.
  • Vomiting, indigestion, burping and bloating.
  • Feeling full early, and less appetite.
  • Tiredness, and headache.

Serious, and rare

  • Pancreatitis: severe, lasting pain in the upper abdomen that may spread to the back, with or without vomiting.
  • Gallbladder problems, including gallstones, which are more likely when body weight falls quickly.
  • Dehydration from vomiting or diarrhoea, which can strain the kidneys.
  • Low blood sugar, mainly when it is combined with insulin or a sulfonylurea.
  • Allergic reactions, rare but serious.
  • A history of medullary thyroid cancer or MEN 2 in you or your family is a reason it is not used.

Stop and get medical help at once for severe abdominal pain, repeated vomiting, signs of an allergic reaction, or sudden changes in vision. Tell the doctor about pregnancy plans first: these are not used in pregnancy.

Questions people ask

Which is stronger, Mounjaro or Ozempic?

In SURMOUNT-5, average reduction in body weight was larger with tirzepatide than with semaglutide 2.4 mg. Stronger is not the same as right for you; a doctor weighs your history and tolerance.

Can I switch from Ozempic to Mounjaro?

Switching is a prescribing decision. A doctor sets the starting strength of the new one and the timing of the change.

Is tirzepatide vs semaglutide the same question?

Yes. Mounjaro is a brand of tirzepatide and Ozempic is a brand of semaglutide.

Every source, in full

  1. [1] Ozempic: EPAR and product information

    European Medicines Agency, 2025. The full label: Ozempic is approved for adults with type 2 diabetes, with its warnings and the side effects seen in trials.

    Read the source
  2. [2] Mounjaro: EPAR and product information

    European Medicines Agency, 2025. The full label: approved uses, how it is started and stepped up, warnings, and the side effects seen in trials with how often each occurred.

    Read the source
  3. [3] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)

    New England Journal of Medicine, 2025. Head to head over 72 weeks, average body-weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide 2.4 mg.

    Read the source
  4. [4] First Indian cohort study on tirzepatide and semaglutide, reported

    ThePrint, 2026. In 150 people treated at one Indian hospital, the median reduction in body weight at about six months was 8.2%, and somewhat larger with tirzepatide than with semaglutide.

    Read the source
  5. [5] Eli Lilly launches Mounjaro in India

    DD News, 2025. Lilly launched Mounjaro in India after approval from the national regulator, for type 2 diabetes and for chronic weight management in adults.

    Read the source
  6. [6] Novo Nordisk's Wegovy gets CDSCO nod for fatty liver disease indication

    Business Standard, 2026. Wegovy, launched in India in June 2025 for chronic weight management, received a further approval from the national regulator in July 2026.

    Read the source
  7. [7] DCGI letter to states on the sale and promotion of GLP-1 receptor agonists, 27 March 2026

    Central Drugs Standard Control Organisation, via Medical Dialogues, 2026. Directs states to ensure these products are sold only through authorised channels, strictly in line with their approved indications and labelling.

    Read the source
  8. [8] Body composition changes with semaglutide in the STEP 1 body-composition substudy, reviewed

    Postgraduate Medicine, 2022. In the STEP 1 body-composition substudy, roughly 40% of the total body weight lost was lean mass rather than fat.

    Read the source
  9. [9] Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension

    Diabetes, Obesity and Metabolism, 2022. One year after semaglutide was stopped, participants had regained about two-thirds of the body weight they had lost.

    Read the source
  10. [10] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4)

    JAMA, 2024. After 36 weeks on tirzepatide, people switched to placebo regained about 14% of body weight by week 88; people who continued went on to a further 5.5% reduction.

    Read the source

Talk to a doctor about your own results.

A registered doctor reads your blood report and your history, and decides with you what comes next.